Table III.
Univariate and multivariate analyses of clinical characteristics for overall survival of patients with advanced non-small cell lung cancer.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age (<60/≥60 years) | 1.172 | 0.902–1.523 | 0.234 | 1.248 | 0.955–1.632 | 0.105 |
| Sex (Male/female) | 0.837 | 0.641–1.093 | 0.192 | 0.827 | 0.560–1.222 | 0.340 |
| Stage (III/IV) | 0.975 | 0.682–1.393 | 0.889 | 1.042 | 0.724–1.500 | 0.824 |
| Histological type (Adeno/sqcc) | 0.577 | 0.415–0.801 | 0.003 | 0.582 | 0.401–0.846 | 0.005 |
| Smoking history (None/yes) | 0.882 | 0.680–1.145 | 0.345 | 1.116 | 0.753–1.653 | 0.586 |
| ECOG PS (0+1/2) | 1.223 | 0.806–1.854 | 0.344 | 1.316 | 0.861–2.012 | 0.204 |
| Tumor location (Left/right) | 1.003 | 0.769–1.308 | 0.982 | 0.997 | 0.763–1.302 | 0.981 |
| NWR (≥0.67/<0.67) | 0.669 | 0.512–0.875 | 0.003 | 0.673 | 0.511–0.888 | 0.005 |
| NLR (≥2.85/<2.85) | 0.718 | 0.549–0.938 | 0.015 | 0.703 | 0.530–0.931 | 0.014 |
| PWR (≥37.23/<37.23) | 1.174 | 0.904–1.525 | 0.228 | 1.172 | 0.889–1.544 | 0.260 |
| PLR (≥166.56/<166.56) | 0.790 | 0.599–1.042 | 0.095 | 0.789 | 0.594–1.047 | 0.101 |
| MWR (≥0.074/<0.074) | 0.852 | 0.656–1.106 | 0.228 | 0.863 | 0.657–1.132 | 0.287 |
| MLR (≥0.31/<0.31) | 0.692 | 0.531–0.901 | 0.006 | 0.669 | 0.504–0.889 | 0.006 |
| LWR (≥0.24/<0.24) | 1.318 | 1.008–1.723 | 0.043 | 1.351 | 1.022–1.785 | 0.034 |
Adeno, adenocarcinoma; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, hazard ratio; LWR, lymphocyte/white blood cell ratio; MLR, monocyte/lymphocyte ratio; MWR, monocyte/white blood cell ratio; NLR, neutrophil/lymphocyte ratio; NWR, neutrophil/white blood cell ratio; PLR, platelet/lymphocyte ratio; PWR, platelet/white blood cell ratio; Sqcc, squamous cell carcinoma.